Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (23)
Riccardo Scotto, Antonio Riccardo Buonomo, Stefania De Pascalis, Mariagiovanna Nerilli, Biagio Pinchera, Laura Staiano, Simona Mercinelli, Letizia Cattaneo, Maria Stanzione, Gianfranca Stornaiuolo, Salvatore Martini, Vincenzo Messina, Carmine Coppola, Nicola Coppola & Ivan Gentile. (2021) Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life ‘LIver Network Activity’ (LINA) cohort update results. Expert Review of Gastroenterology & Hepatology 15:9, pages 1057-1063.
Read now
Read now
Carol Stanciu, Anca Trifan, Cristina Muzica & Catalin Sfarti. (2019) Efficacy and safety of alisporivir for the treatment of hepatitis C infection. Expert Opinion on Pharmacotherapy 20:4, pages 379-384.
Read now
Read now
Isabella Esposito, Sebastián Marciano & Julieta Trinks. (2018) Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. Expert Opinion on Drug Metabolism & Toxicology 14:6, pages 649-657.
Read now
Read now
Allister Sebastian Lee, Mieke L van Driel & Darrell HG Crawford. (2017) The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia. ClinicoEconomics and Outcomes Research 9, pages 595-607.
Read now
Read now
Ivan Gentile, Alberto E. Maraolo, Massimo Niola, Vincenzo Graziano, Guglielmo Borgia & Mariano Paternoster. (2016) Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Review of Gastroenterology & Hepatology 10:11, pages 1227-1234.
Read now
Read now
Guglielmo Borgia, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, Riccardo Scotto & Ivan Gentile. (2016) The therapeutic potential of new investigational hepatitis C virus translation inhibitors. Expert Opinion on Investigational Drugs 25:10, pages 1209-1214.
Read now
Read now
Laura Benítez-Gutiérrez, Pablo Barreiro, Pablo Labarga, Carmen de Mendoza, José V. Fernandez-Montero, Ana Arias, José M. Peña & Vicente Soriano. (2016) Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opinion on Pharmacotherapy 17:9, pages 1215-1223.
Read now
Read now
Ivan Gentile, Riccardo Scotto, Emanuela Zappulo, Antonio Riccardo Buonomo, Biagio Pinchera & Guglielmo Borgia. (2016) Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opinion on Investigational Drugs 25:5, pages 557-572.
Read now
Read now
José-R. Blanco & Antonio Rivero-Juarez. (2016) HCV genotype 3: a wolf in sheep’s clothing. Expert Review of Anti-infective Therapy 14:2, pages 149-152.
Read now
Read now
Vincent Soriano, Pablo Labarga, Carmen de Mendoza, José V Fernández-Montero, Isabella Esposito, Laura Benítez-Gutiérrez, José M Peña & Pablo Barreiro. (2016) New hepatitis C therapies for special patient populations. Expert Opinion on Pharmacotherapy 17:2, pages 217-229.
Read now
Read now
Ivan Gentile, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, Emanuela Zappulo & Guglielmo Borgia. (2015) The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opinion on Drug Discovery 10:12, pages 1363-1377.
Read now
Read now
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Riccardo Scotto & Guglielmo Borgia. (2015) Asunaprevir for hepatitis C: a safety evaluation. Expert Opinion on Drug Safety 14:10, pages 1631-1646.
Read now
Read now
Isabella Esposito, Pablo Labarga, Pablo Barreiro, José V Fernandez-Montero, Carmen de Mendoza, Laura Benítez-Gutiérrez, José M Peña & Vicente Soriano. (2015) Dual antiviral therapy for HIV and hepatitis C – drug interactions and side effects. Expert Opinion on Drug Safety 14:9, pages 1421-1434.
Read now
Read now
Jerzy Jaroszewicz, Marta Flisiak-Jackiewicz, Dariusz Lebensztejn & Robert Flisiak. (2015) Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. Expert Opinion on Investigational Drugs 24:9, pages 1229-1239.
Read now
Read now
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Alberto Enrico Maraolo & Guglielmo Borgia. (2015) Beclabuvir for the treatment of hepatitis C. Expert Opinion on Investigational Drugs 24:8, pages 1111-1121.
Read now
Read now
Adriaan J van der Meer. (2015) Achieving sustained virological response: what’s the impact on further hepatitis C virus-related disease?. Expert Review of Gastroenterology & Hepatology 9:5, pages 559-566.
Read now
Read now
Ashley Arezou Minaei & Kris V Kowdley. (2015) ABT-450/ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert Opinion on Pharmacotherapy 16:6, pages 929-937.
Read now
Read now
Vincent Soriano, Pablo Labarga, Pablo Barreiro, José V Fernandez-Montero, Carmen de Mendoza, Isabella Esposito, Laura Benítez-Gutiérrez & José M Peña. (2015) Drug interactions with new hepatitis C oral drugs. Expert Opinion on Drug Metabolism & Toxicology 11:3, pages 333-341.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo & Guglielmo Borgia. (2015) Discontinued drugs in 2012 – 2013: hepatitis C virus infection. Expert Opinion on Investigational Drugs 24:2, pages 239-251.
Read now
Read now
Sheng-Shun Yang & Jia-Horng Kao. (2015) Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. Expert Review of Gastroenterology & Hepatology 9:1, pages 9-20.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Giuseppina Minei, Filomena Morisco, Francesco Borrelli, Nicola Coppola & Guglielmo Borgia. (2014) Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Therapeutics and Clinical Risk Management 10, pages 493-504.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Nicola Coppola & Guglielmo Borgia. (2014) GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. Expert Review of Anti-infective Therapy 12:10, pages 1179-1186.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo & Guglielmo Borgia. (2014) Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Review of Anti-infective Therapy 12:9, pages 1033-1043.
Read now
Read now
Articles from other publishers (17)
Vasilios Papastergiou, Hariklia Kranidioti & Spilios Manolakopoulos. 2021. Hepatitis C: Care and Treatment. Hepatitis C: Care and Treatment
97
117
.
Waleed Ismail, Amr Hanafy & Mohammed Abdelsattar. (2019) The outcome of the sofosbuvir Based Therapy in the treatment of Hepatitis C Virus Genotype 4 in Egyptian patients. african journal of gastroenterology and hepatology 2:1, pages 10-27.
Crossref
Crossref
Ivan Gentile, Antonio Riccardo Buonomo, Riccardo Scotto, Emanuela Zappulo & Guglielmo Borgia. (2017) Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage. European Journal of Internal Medicine 46, pages e45-e47.
Crossref
Crossref
Wikrom Karnsakul & Kathleen B. Schwarz. (2017) Hepatitis B and C. Pediatric Clinics of North America 64:3, pages 641-658.
Crossref
Crossref
L. Benítez-Gutiérrez, C. de Mendoza, I. Baños, A. Duca, A. Arias, A. Treviño, S. Requena, M.J. Citores & V. Cuervas-Mons. (2016) Drug-Induced Lung Injury in a Liver Transplant Patient Treated With Sofosbuvir. Transplantation Proceedings 48:7, pages 2515-2518.
Crossref
Crossref
Jia-Wu Zhu, Feng-Liang Liu, Dan Mu, De-Yao Deng & Yong-Tang Zheng. (2016) Increased expression and dysregulated association of restriction factors and type I interferon in HIV, HCV mono- and co-infected patients. Journal of Medical Virology 88:6, pages 987-995.
Crossref
Crossref
Sheng-Shun Yang & Jia-Horng Kao. (2015) Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. Hepatology International 10:2, pages 258-266.
Crossref
Crossref
Mona Abdelmonem Esmail, Noha A. Hassuna, Khalda Sayed Amr, Eman Ramadan Ghazawy & Mohamed Abdel-Hamid. (2016) Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients. Journal of Medical Virology 88:3, pages 481-486.
Crossref
Crossref
Vincent Soriano, Pablo Labarga, José V Fernandez-Montero, Carmen de Mendoza, Isabella Esposito, Laura Benítez-Gutiérrez & Pablo Barreiro. (2016) Hepatitis C Cure with Antiviral Therapy – Benefits beyond the Liver. Antiviral Therapy 21:1, pages 1-8.
Crossref
Crossref
Christoph R Werner, Carolin Franz, Daniel P Egetemeyr, Robert Beck, Nisar P Malek, Ulrich M Lauer & Christoph P Berg. (2015) First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort. Virology Journal 12:1.
Crossref
Crossref
Mohammad Saeid Rezaee-Zavareh, Reza Hadi, Hamidreza Karimi-Sari, Mohammad Hossein Khosravi, Reza Ajudani, Fardin Dolatimehr, Mahdi Ramezani-Binabaj, Seyyed Mohammad Miri & Seyed Moayed Alavian. (2015) Occult HCV Infection: The Current State of Knowledge. Iranian Red Crescent Medical Journal 17:11.
Crossref
Crossref
Amy B. Dounay. 2015. Innovative Drug Synthesis. Innovative Drug Synthesis
15
42
.
Andrew J. Muir. (2015) Understanding the Complexities of Cirrhosis. Clinical Therapeutics 37:8, pages 1822-1836.
Crossref
Crossref
Ivan Gentile & Guglielmo Borgia. (2015) A pill a day keeps HCV away. The Lancet Infectious Diseases 15:6, pages 616-617.
Crossref
Crossref
Ming-Zhi Zhang, Qiong Chen & Guang-Fu Yang. (2015) A review on recent developments of indole-containing antiviral agents. European Journal of Medicinal Chemistry 89, pages 421-441.
Crossref
Crossref
Ivan Gentile & Guglielmo Borgia. (2014) Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment. Evidence Based Medicine 19:6, pages 223-224.
Crossref
Crossref
C. Brauner, T.O. Lankisch, P. Fytili, J. Jaroszewicz, F. Lehner, H. Barg‐Hock, J. Klempnauer, E. Jaeckel, M.P. Manns, H. Wedemeyer & A.A. Negm. (2014) Clinical value and safety of liver biopsies in patients transplanted for hepatitis C virus‐related end‐stage liver disease. Transplant Infectious Disease 16:6, pages 958-967.
Crossref
Crossref